Eagle Pharmaceuticals (EGRX) : Eagle Pharmaceuticals (EGRX) had a healthy money flow of $0.32 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $0.51 million, whereas, investors only sold shares worth $0.2 million on downticks. The stock closed the day with an up-down ratio of 2.61.The money flow in the block trades to the tune of $0 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0 million worth of transactions were on upticks. Eagle Pharmaceuticals (EGRX) stock slid $0.2 intraday and traded at 61.85, a change of -0.32% over previous days close. However, for the week, the company shares are 24.85% compared to previous weeks close.
Shares of Eagle Pharmaceuticals Inc. rose by 25.43% in the last five trading days and 28.14% for the last 4 weeks. Eagle Pharmaceuticals Inc. is up 37.24% in the last 3-month period. Year-to-Date the stock performance stands at -31.59%.
Eagle Pharmaceuticals (NASDAQ:EGRX): The stock opened at $62.55 on Monday but the bulls could not build on the opening and the stock topped out at $62.72 for the day. The stock traded down to $60.02 during the day, due to lack of any buying support eventually closed down at $60.66 with a loss of -2.24% for the day. The stock had closed at $62.05 on the previous day. The total traded volume was 384,438 shares.
In a related news,The director officer (President and CEO) of Eagle Pharmaceuticals, Inc., Tarriff Scott sold 30,765 shares at $40.63 on April 1, 2016. The Insider selling transaction had a total value worth of $1,249,982. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101, EP-3102, Ryanodex, EP-4104, EP-6101, EP-5101, EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.